Rodriguez2025antibodyvariableregionmapping
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive Plus
ORGANISM(S): Mus Musculus (ncbitaxon:10090)
SUBMITTER: 
Julian Whitelegge
PROVIDER: MSV000097881 | MassIVE | Tue May 13 16:14:00 BST 2025
SECONDARY ACCESSION(S): PXD063901
REPOSITORIES: MassIVE
Similar Datasets
Project description:Interventions: Experimental group:Dietary fiber;Control:Non-Dietary fiber
Primary outcome(s): Hgb, ALB, PAB, TRF, LYM, CD3+, CD3+CD4+, CD3+CD8+, CD16+CD56+, CD19+, IgA, IgG, IgM;16S rRNA gene v3v4 variable region
Study Design: Randomized parallel controlled trial
| 2666161 | ecrin-mdr-crc
Project description:IgG was collected from virgin and pregnant listeria challenged mouse plasma. Polyclonal IgG was analyzed by reduction, alkylation, and LC-MS with top-down MS/MS (HCD and ETD)to look for glycosylation PTMs
2022-06-28 | PXD033357 | Pride
Project description:Tyson1991 - Cell Cycle 2 var
Mathematical model of the interactions of cdc2 and cyclin.
Description taken from the original Cellerator version of the model ( Tyson (1991, 2 variables)
at http://www.cellerator.org
).
This model is described in the article:
Modeling the cell division cycle: cdc2 and cyclin interactions.
Tyson JJ.
Proc. Natl. Acad. Sci. U.S.A. 1991; 88(16); 7328-32
Abstract:
The proteins cdc2 and cyclin form a heterodimer (maturation promoting factor) that controls the major events of the cell cycle. A mathematical model for the interactions of cdc2 and cyclin is constructed. Simulation and analysis of the model show that the control system can operate in three modes: as a steady state with high maturation promoting factor activity, as a spontaneous oscillator, or as an excitable switch. We associate the steady state with metaphase arrest in unfertilized eggs, the spontaneous oscillations with rapid division cycles in early embryos, and the excitable switch with growth-controlled division cycles typical of nonembryonic cells.
This is a two variable reduction of the larger 6-variable model published in the same paper. The equations are:
u'= k4(v-u)(alpha+u^2)-k6*u
v'=kappa-k6*u
z= v-u
with kappa = k1[aa]/[CT]
In the present implementation, an additional variable z is introduced with z = v-u is made, so that the different variables be interpreted as follows:
u=[activeMPF]/[CT]
v=([cyclin]+[preMPF]+[activeMPF])/[CT]
z=([ cyclin]+[preMPF])/[CT]
with [CT]=[CDC2]+{CDC2P]+[preMPF]+[aMPF].
The reactions included are only to show the flows between z and u, and do not influence the species, as they all are set to boundaryCondition=True
, meaning, that they are only determined by the rate rules (explicit differential equations) and assignment rules.
If you set boundaryCondition=False
and remove the rate rules for v, u and the the assignment rule for z, you get the more symmetrical, but equivalent, version from the Cellerator repository:
u'= k4*z*(alpha+u^2)-k6*u
z'=kappa-z*(alpha+u^2)
This model is hosted on BioModels Database
and identified by: BIOMD0000000006
.
To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models
.
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication
for more information.
2024-09-02 | BIOMD0000000006 | BioModels
Project description:The transplacental transfer of maternal IgG to the developing fetus is critical for infant protection against infectious pathogens in the first year of life. However, factors that modulate the transplacental transfer efficiency of maternal IgG that could be harnessed for maternal vaccine design remain largely undefined. HIV-infected women have impaired placental IgG transfer, yet the mechanism underlying this impaired transfer is unknown, presenting an opportunity to explore factors that contribute to the efficiency of placental IgG transfer. We measured the transplacental transfer efficiency of maternal HIV and other pathogen-specific IgG in historical U.S. (n=120) and Malawian (n=47) cohorts of HIV-infected mothers and their HIV58 exposed uninfected and HIV-infected infants. We then examined the role of maternal HIV disease progression, infant factors, placental Fc receptor expression, and IgG Fc region subclass and glycan signatures and their association with transplacental transfer efficiency of maternal antigen-specific IgG. We established 3 distinct phenotypes of placental IgG transfer efficiency in HIV-infected women, including: 1) efficient transfer of the majority of antigen-specific IgG populations; 2) generally poor IgG transfer phenotype that was strongly associated with maternal CD4+ T cell counts, hypergammaglobulinemia, and frequently yielded non-protective levels of vaccine-specific IgG; and 3) variable transfer of IgG across distinct antigen specificities. Interestingly, maternal IgG characteristics, such as binding to placentally expressed Fc receptors FcgRIIa and FcgRIIIa, IgG subclass frequency, and Fc region glycan profiles were associated with placental IgG transfer efficiency. These maternal IgG transplacental transfer determinants were distinct among different antigen-specific IgG populations. Our findings suggest that in HIV-infected women, both maternal disease progression and Fc region characteristics modulate the selective placental transfer of distinct IgG subpopulations, with implications for both the health of HIV-exposed uninfected infants and maternal vaccine design.
2019-09-11 | GSE129272 | GEO
Project description:In this study, we systematically evaluated reduction and alkylation of proteins using three reducing agents (DTT, TCEP, and BME) in combination with four alkylation agents (IAA, IAC, AA, and CAA). We tested these conditions using strong anion exchange (SAX) fractionated in-solution digests and in-gel digested fractions of samples enriched for cytosolic proteins of HeLa cells. We analyzed the data using Proteome Discoverer 2 in combination with the MASCOT search engine with different combinations of variable and fixed modifications as well as error tolerant and mass tolerant searches. Furthermore, we compared IAA and AA alkylated samples by dimethyl labeling and performed multi stage activation triggered by the neutral loss of alkylated methionine side chains. This led to the identification of prominent offside alkylation due to iodine containing reagents at tyrosine, serine, threonine, histidine, lysine, methionine, aspartic and glutamic acid as well as the peptide N-terminus with varying abundances based on the reduction and alkylation reagents used.
2017-05-30 | PXD005183 | Pride
Project description:Import of ferrous iron (Fe2+) via the plasma membrane ZIP transporter IRON-REGULATED TRANSPORTER1 (IRT1) bears the risk of oxidative damage and lipid peroxidation. The plasma membrane-associated SEC14-like lipid transfer protein PATL2 interacts with the large cytosolic loop and variable region of IRT1 (IRT1vr). PATL2 affects Fe reduction and reactive oxygen species-related responses in roots and alleviates lipid peroxidation upon Fe acquisition. PATL2 binds α-tocopherol, an antioxidant of the vitamin E group.
2023-04-25 | PXD032079 | Pride
Project description:Elevated N-linked glycosylation of immunoglobulin G variable regions (IgG-VN-Glyc) is an emerging molecular phenotype associated with autoimmune disorders. To test the broader specificity of elevated IgG-VN-Glyc, we studied patients with distinct subtypes of myasthenia gravis (MG), a B cell-mediated autoimmune disease. Our experimental design included adaptive immune receptor repertoire sequencing to quantify and characterize N-glycosylation sites in the global B cell receptor repertoire, proteomics to examine glycosylation patterns of the circulating IgG, and production of human-derived recombinant autoantibodies, which were studied with mass spectrometry and antigen binding assays to confirm occupation of glycosylation sites and determine whether they alter binding. We found that the frequency of IgG-VN-Glyc motifs was increased in the B cell repertoire of MG patients when compared to healthy donors. Motifs were introduced by both biased V gene segment usage and somatic hypermutation. IgG-VN-Glyc could be observed in the circulating IgG in a subset of MG patients. Autoantigen binding, by patient-derived MG autoantigen-specific monoclonal antibodies with experimentally confirmed presence of IgG-VN-Glyc, was not altered by the glycosylation. Our findings extend prior work on patterns of variable region N-linked glycosylation in autoimmunity to MG subtypes. Although occupied IgG-VN-Glyc motifs are found on MG autoantigen-specific monoclonal antibodies, they are not required for binding to the autoantigen in this disease.
2021-08-13 | GSE182038 | GEO
Project description:Type 1 diabetes mellitus results from an autoimmune destruction of pancreatic beta-cells. Based on findings suggesting NF-kappa B plays a role in beta cell apoptosis, we blocked NF-kappa B activation in cytokine-exposed FACS sorted beta cells by a recombinant adenovirus (AdI kappa B((SA)2)) containing an inhibitor of NF kappa B alpha (I kappa Bac) super-repressor (S32A/S36A). The expression profile was then analyzed with the Affymetrix RG U34a microarray.
2006-06-16 | E-CBIL-9 | biostudies-arrayexpress
Project description:The question whether and which non-human peptides or proteins are present in human milk was raised many decades ago. However, due to cross-reactivity or nonspecific antibody recognition, the accuracy of detection by immunochemical methods has been a concern. Additionally, the relative low-abundance of non-human peptides/proteins in the complex milk sample makes them a challenging target to detect. Here, by deep proteome profiling we detected several non-human peptides, which could be grouped as non-human proteins. We next estimated their concentration in human milk by combining data-dependent shotgun proteomics and parallel reaction monitoring. First, we fractionated human milk at the protein level by using sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by reduction, alkylation and in-gel digestion. The resulted peptide mixtures were subjected to proteomics analysis. We were able to detect 1577 human proteins in human milk. Additionally, we identified 109 non-human peptides, of which 71 were grouped in to 36 non-human proteins. In the next step, we targeted 37 non-human peptides and 9 of them could be repeatedly quantified in human milk samples. Peptides/proteins originating from bovine milk products were the dominant non-human proteins observed, notably bovine caseins (α-S1-, α-S2-, β-, κ-caseins) and β-lactoglobulin.
2018-12-04 | PXD011599 | Pride
Project description:The question whether and which non-human peptides or proteins are present in human milk was raised many decades ago. However, due to cross-reactivity or nonspecific antibody recognition, the accuracy of detection by immunochemical methods has been a concern. Additionally, the relative low-abundance of non-human peptides/proteins in the complex milk sample makes them a challenging target to detect. Here, by deep proteome profiling we detected several non-human peptides, which could be grouped as non-human proteins. We next estimated their concentration in human milk by combining data-dependent shotgun proteomics and parallel reaction monitoring. First, we fractionated human milk at the protein level by using sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by reduction, alkylation and in-gel digestion. The resulted peptide mixtures were subjected to proteomics analysis. We were able to detect 1577 human proteins in human milk. Additionally, we identified 109 non-human peptides, of which 71 were grouped in to 36 non-human proteins. In the next step, we targeted 37 non-human peptides and 9 of them could be repeatedly quantified in human milk samples. Peptides/proteins originating from bovine milk products were the dominant non-human proteins observed, notably bovine caseins (α-S1-, α-S2-, β-, κ-caseins) and β-lactoglobulin.
2020-11-04 | PXD010413 | Pride